Drug Trial Radar · NCT06454240
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Jul 17, 2024
Primary completion
Jan 29, 2026
Study completion Apr 23, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups. The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
lunsekimigDrug
Pharmaceutical form:solution for injection-Route of administration:subcutaneous
placeboDrug
Pharmaceutical form:solution for injection-Route of administration:subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in bilateral endoscopic nasal polyp score (NPS).Time frame: From baseline to Week 24
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Allergy & Rheumatology- Site Number : 8400005
La Jolla, California
Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003
Roseville, California
Senta Clinic- Site Number : 8400025
San Diego, California
James A Haley Veterans' Hospital- Site Number : 8400015
Tampa, Florida
Emory University Hospital Midtown- Site Number : 8400012
Atlanta, Georgia
The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002
Boise, Idaho
Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016
Boston, Massachusetts
Essential Medical Research- Site Number : 8400020
Tulsa, Oklahoma
McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017
Bellaire, Texas
Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004
Dallas, Texas
Berkson Medical - McKinney- Site Number : 8400014
McKinney, Texas
Alamo ENT Associates Site Number : 8400001
San Antonio, Texas
Advanced Research Institute - Odgen- Site Number : 8400022
Ogden, Utah
Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008
Norfolk, Virginia
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320003
Mendoza, Argentina
Investigational Site Number : 0320002
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0560002
Ghent, Belgium
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 1000001
Sofia, Bulgaria
Investigational Site Number : 6160004
Poznan, Poland
Investigational Site Number : 6160007
Wroclaw, Poland
Investigational Site Number : 6160002
Krakow, Lesser Poland Voivodeship, Poland
Investigational Site Number : 6160001
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6160005
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6160003
Katowice, Silesian Voivodeship, Poland
Investigational Site Number : 8260003
Manchester, United Kingdom
Investigational Site Number : 8260001
Newcastle upon Tyne, United Kingdom
Investigational Site Number : 8260004
Gloucester, Gloucestershire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.